Tag Archives: prisoner healthcare

Linkages to Care for Current/Former Incarcerated Citizens Living with Hepatitis C

HEAL Blog is the recipient of the ADAP Advocacy Association’s 2015-2016 ADAP Social Media Campaign of the Year Award
By: Marcus J. Hopkins, Blogger

The Community Access National Network (CANN) will be hosting a roundtable at the headquarters of the Pharmaceutical Research and Manufacturers of America (PhRMA) on Thursday, May 11th, 2017, on the topic of Hepatitis C (HCV) in Incarcerated Populations. The roundtable will focus on various aspects of treated HCV in prison and jail settings, including the Constitutional requirement that all inmates receive treatment, as well as various barriers that prevent inmates from receiving screening and treatment.

Invite for the Community Roundtable on Linkages to Care for Current/Former Incarcerated Citizens Living with Hepatitis C

Current estimates indicate that between 10-35% of inmates are infected with HCV, and that roughly half of those inmates don’t know that they’re infected. These estimates are, however, limited by inconsistent or non-existent screening protocols, reporting requirements, and various bureaucratic hurdles that prevent inmates from being screened. Furthermore, there are no penalties in place that hold prison and jail systems accountable for failing to screen inmates, which often results in costly lawsuits.

The Federal Bureau of Prisons released a new set of screening guidelines for HCV in October 2016, which included the recommendation that all prisons and jails adopt an “Opt-Out” screening process (Federal Bureau of Prisons, 2016). This strategy requires that HCV screening becomes part of a routine practice, and that inmates must provide “informed refusal” in order not to be screened. This strategy would be instrumental in combating the HCV epidemic running rampant among inmate populations, as well as for data gathering purposes.

Implementing this strategy across all prisons and jails in the U.S. in a difficult proposal, in no small part because it will be expensive. What makes it so expensive is that screening, itself, isn’t cheap – at least not the confirmatory tests; additionally, if prisons and jails discover that an inmate has HCV, or any other life-threatening illness, they are required under the 8th Amendment of the U.S. Constitution to treat that inmate’s illness (Estelle v. Gamble). That last part can cost prison systems tens of thousands of dollars fear each infected inmate – costs that will explode pharmacy and healthcare budgets in the short-term, but will save money in the long-term.

Furthermore, prisons appear to be extremely inconsistent about what prices they pay for drugs. The Wall Street Journal (WSJ) published a report in September 2016 per-patient cost paid by state prisons to treat HCV using Gilead’s Harvoni: the prices ranged from $46,021 in North Dakota to $91,014 in Georgia (Loftus & Fields, 2016). These numbers indicate the need for more price stabilization in the U.S. prison systems, or at the very least, consolidated price negotiation.

While the roundtable is open to the public, seating is limited. Interested parties can sign up for the event at the following address: http://tiicann.org/events.html

References:

__________

Disclaimer: HEAL Blogs do not necessarily reflect the views of the Community Access National Network (CANN), but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about Hepatitis-related issues and updates. Please note that the content of some of the HEAL Blogs might be graphic due to the nature of the issues being addressed in it.

Advertisements

Leave a comment

Filed under Uncategorized

Many State Prisoners Can’t Access Hepatitis C Therapies

HEAL Blog is the recipient of the ADAP Advocacy Association’s 2015-2016 ADAP Social Media Campaign of the Year Award
By: Marcus J. Hopkins, Blogger

Here, at HEAL Blog, we frequently speak about issues related to the cost of newer Direct Acting Agents (DAAs) to treat Hepatitis C (HCV). We’ve also covered issues related to HCV treatment in America’s prison system. Our verdict, then, as now, stands – the only U.S. citizens who are Constitutionally guaranteed healthcare are the least likely to receive treatment for HCV.

Image of the red cross behind bars

Photo Source: Solidarity Watch

A recent study published in Health Affairs confirms our observations from earlier this year: inmates who are infected with HCV are not receiving proper treatment, largely because the cost of medications puts the drugs far out of reach. For co-infected patients, the HCV is likelier to kill them, before the HIV ever will.

The finding that is most troubling is that, of the 106,266 inmates known to have HCV (reported by 41 states), only 949 inmates were receiving any form of HCV treatment by January 01, 2015 – 0.89% of reported inmates. This means that fewer than 1% of reported inmates are receiving their Constitutionally guaranteed treatment.

Another finding that’s equally appalling is that numerous state departments of corrections were receiving much smaller discounts than other state agencies. The US Senate Committee of Finance’s 2015 report on the pricing of Sovaldi and Harvoni noted that the Federal Bureau of Prisons, Department of Defense, and Department of Veterans Affairs receive at least a 24% discount on those drugs, Medicaid receives at least a 23% discount, and that the V.A. and Medicaid programs that accepted the conditions of offered rebates may receive more than a 50% discount. In contrast, ten of eighteen state departments of corrections received less than a 10% discount on Sovaldi as of September 30, 2015, with Michigan paying the full $84,000; five of nineteen states received less than a 10% discount on Harvoni.

While this study does not claim to claim to represent an estimate of HCV prevalence in US prison populations, it does admit that this limitation means that there is likely a far greater prevalence of HCV than the 106,266 inmates listed in the report. This has been suspected for some time, and was specifically alleged in a Tennessee inmate’s case against the state for withholding treatment from prisoner. A May 2016 report by the Tennessean also found that many prisons in the state simply do not test incoming prisoners, because doing so might result in a positive HCV result; admitting that the inmates have HCV would require them to treat the inmates.

While Gilead Sciences (makers of Sovaldi, Harvoni, and Epclusa) justifies the price of their medications by comparing the cost of one course of treatment to the cost of multi-year treatment costs for other diseases, state budgets are not made in such a way that accommodates that pricing philosophy, particularly if patients/inmates become re-infected. With prison budgets already strained beyond the breaking point to provide for the basic needs of their inmates, having them pay price much higher than those paid by either Medicaid or the V.A. is simply a recipe for disaster.
__________

Disclaimer: HEAL Blogs do not necessarily reflect the views of the Community Access National Network (CANN), but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about Hepatitis-related issues and updates. Please note that the content of some of the HEAL Blogs might be graphic due to the nature of the issues being addressed in it.

Leave a comment

Filed under Uncategorized